Immune-mediated necrotizing myopathy (IMNM), also called necrotizing autoimmune myopathy (NAM), is a rare but serious muscle disease strongly associated with autoantibodies to either signal recognition protein (SRP-IgG) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR-IgG). Our testing can provide earlier identification and treatment initiation in patients with IMNM, which is critical to preventing further harm.
2/3
2/3 of IMNM patients will be seropositive for HMGCR-IgG or SRP-IgG
Necrotizing autoimmune myopathy Test menu
Key testing
Advantages
Highlights
In late 2019, after months of looking for a reason for his rapid loss of muscular function, David Voeltz got an answer: he had necrotizing autoimmune myopathy. Today, after nearly two years of treatment, David has a renewed lease on life and keen appreciation for the Mayo Clinic team that confirmed his diagnosis.
This “Specialty Testing” webinar will discuss the diagnosis, pathological understanding, and current best treatment options for necrotizing autoimmune myopathy.
Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.